{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"2-aminoadipic-2-oxoadipic-aciduria","columns":[{"gene":"","key":"population-e6e1af9092499c7c3277","label":"Alpha-aminoadipic and alpha-ketoadipic aciduria","mondoId":"MONDO:0008774","onsetQualifier":null,"originColumnKey":"MONDO:0008774/OMIM:204750","originalViews":[{"key":"MONDO:0008774/OMIM:204750","label":"Alpha-aminoadipic and alpha-ketoadipic aciduria","scopeLabel":"OMIM:204750","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["046cdc10796d22de54e23ed306a203d340375f03425a8d1e97ee3042e620a510","064d483b47b640ff0617b3d45280f50b6b1a94ae4b58bcbdb45e0e3a89348f5a","143f0e94008daad24c5e08aefc04134e39bf3da75b227850bc7614b362edcad8","56be728bb0eb946a69c962dcb04f4d8652a2f780d71f9cd2938461919c90cae4","9a4c90eb3c60570106c5e0d55053309fd2e83871c49572b862b0da8d57bab820","9f4062cd3b272387ed78b0b25fa62fe9c8ea0dcbdbc255613be9a021298daab3","a668e9a7f658a805ea3e0c56d4f60ab234d13c75b48ebac99cd8a90a342ada84","fce96f6caa465e6fcdd6025af0e517474dc553ce524b20e36983f3000fc20e08"],"recordQualifiers":{},"scopeLabel":"OMIM:204750","sourceIds":["OMIM:204750"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."},{"gene":"","key":"population-9135a6643970843ebd20","label":"2-aminoadipic 2-oxoadipic aciduria","mondoId":"MONDO:0008774","onsetQualifier":null,"originColumnKey":"MONDO:0008774/ORPHA:79154","originalViews":[{"key":"MONDO:0008774/ORPHA:79154","label":"2-aminoadipic 2-oxoadipic aciduria","scopeLabel":"ORPHA:79154","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["05d2a8af722f78a99d8be0de2e659838294190ef22fd3803b71c89e8acf724d0","0d410934452ae37fe8f2ff91b3430bf1d3a060051df2c72ea00257f117863eb7","156560153d765bd82ae65ac5755a72c70c9abf7ea017b412859b2a90ea966da3","693f28b4824dd33aa4759906148b62a937c841d7aa24e2354dc86841fcc3eff6","743bc3cc6a3a2856e0086e2df23223c0822c245d3215c212e33c5c8878bfa567","79d56fdafa064d9cbb4076337329a1145433ae7c9b46510a0e567456de185c25","8d15e9bffe27ff31552bee24f5957c89112aef3feeb6a955392b0c1dce00b3e3","ad3abd590acfcc4c8f5e0f4cb77928c16865b804cec161f2f702d096d7f8c22a","bfac1ae8319bdc3a754ffb8b381b5a045fd317294a18bc45cd2dccfe3072386d","c8db93f3d52e31cc0dbff8799e6f018709b90e932d6b5ef82a864308344c61ef","ddc1fbfca1b12ce2e83388836d13584ead3a0abdb67e6930c309a0e8d4f8636f"],"recordQualifiers":{},"scopeLabel":"ORPHA:79154","sourceIds":["ORPHA:79154"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-e6e1af9092499c7c3277","population-9135a6643970843ebd20"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0034465","HP:0410309","HP:0007018","HP:0000717","HP:0000750","HP:6000278","HP:0001263"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":8,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":19,"sourceGroups":{"orphanet":11,"published":8}},"features":[{"hpoId":"HP:0034465","label":"2-hydroxyadipic aciduria","primary":true},{"hpoId":"HP:0410309","label":"Alpha-aminoadipic aciduria","primary":true},{"hpoId":"HP:0007018","label":"Attention deficit hyperactivity disorder","primary":true},{"hpoId":"HP:0000717","label":"Autism","primary":true},{"hpoId":"HP:0000750","label":"Delayed speech and language development","primary":true},{"hpoId":"HP:6000278","label":"Elevated circulating 2-aminoadipic acid concentration","primary":true},{"hpoId":"HP:0001263","label":"Global developmental delay","primary":true},{"hpoId":"HP:0001252","label":"Hypotonia","primary":false},{"hpoId":"HP:0001249","label":"Intellectual disability","primary":false},{"hpoId":"HP:0000252","label":"Microcephaly","primary":false},{"hpoId":"HP:0011342","label":"Mild global developmental delay","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false}],"ledeHtml":"A rare disorder of lysine and tryptophan metabolism characterized by 2-aminoadipic and 2-oxoadipic aciduria. Patients may also present with increased urinary excretion of alpha-hydroxyadipic acid. Variable clinical presentations have been found in patients including hypotonia, developmental delay, mild to severe intellectual disability, ataxia, epilepsy, and behavioral disorders (most commonly attention deficit hyperactivity disorder). However, many individuals with the biochemical phenotype are completely asymptomatic and thus the clinical significance of the condition is questionable.","mondoId":"MONDO:0008774","node":{"canonicalSlug":"2-aminoadipic-2-oxoadipic-aciduria","comparisons":[{"documentSha256":"8538216032a3b1bfc0f221f82a3c32ddbd45f4b5bf56f90c3830b420dea8b5e9","key":"legacy-2-aminoadipic-2-oxoadipic-aciduria","kind":"legacy","label":"2-aminoadipic 2-oxoadipic aciduria","memberIds":["MONDO:0008774"],"mondoId":"MONDO:0008774","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/2-aminoadipic-2-oxoadipic-aciduria.8538216032a3b1bfc0f221f82a3c32ddbd45f4b5bf56f90c3830b420dea8b5e9.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"2-aminoadipic 2-oxoadipic aciduria","originalSourceId":"ORPHA:79154","paragraphs":["A rare disorder of lysine and tryptophan metabolism characterized by 2-aminoadipic and 2-oxoadipic aciduria. Patients may also present with increased urinary excretion of alpha-hydroxyadipic acid. Variable clinical presentations have been found in patients including hypotonia, developmental delay, mild to severe intellectual disability, ataxia, epilepsy, and behavioral disorders (most commonly attention deficit hyperactivity disorder). However, many individuals with the biochemical phenotype are completely asymptomatic and thus the clinical significance of the condition is questionable."],"rawAttribution":"ORPHA:79154","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-21T17:01:20Z","upstream":"ORPHA:79154","url":"https://rarediseases.info.nih.gov/diseases/16708"},"ownColumnKeys":["population-e6e1af9092499c7c3277","population-9135a6643970843ebd20"],"publication":"published","relationships":[{"kind":"parent","label":"inborn disorder of lysine and hydroxylysine metabolism","mondoId":"MONDO:0017351","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"count","key":"046cdc10796d22de54e23ed306a203d340375f03425a8d1e97ee3042e620a510","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204750","disease_name":"Alpha-aminoadipic and alpha-ketoadipic aciduria","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0007018","is_excluded":false,"label":"Attention deficit hyperactivity disorder","onset_id":null,"reference":"PMID:23141293","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"05d2a8af722f78a99d8be0de2e659838294190ef22fd3803b71c89e8acf724d0","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001252","is_excluded":false,"label":"Hypotonia","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"064d483b47b640ff0617b3d45280f50b6b1a94ae4b58bcbdb45e0e3a89348f5a","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:204750","disease_name":"Alpha-aminoadipic and alpha-ketoadipic aciduria","evidence":"PCS","frequency_raw":"4/4","hpo_id":"HP:0410309","is_excluded":false,"label":"Alpha-aminoadipic aciduria","onset_id":null,"reference":"PMID:23141293","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"0d410934452ae37fe8f2ff91b3430bf1d3a060051df2c72ea00257f117863eb7","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0410309","is_excluded":false,"label":"Alpha-aminoadipic aciduria","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"143f0e94008daad24c5e08aefc04134e39bf3da75b227850bc7614b362edcad8","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204750","disease_name":"Alpha-aminoadipic and alpha-ketoadipic aciduria","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0011342","is_excluded":false,"label":"Mild global developmental delay","onset_id":null,"reference":"PMID:23141293","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"156560153d765bd82ae65ac5755a72c70c9abf7ea017b412859b2a90ea966da3","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"56be728bb0eb946a69c962dcb04f4d8652a2f780d71f9cd2938461919c90cae4","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204750","disease_name":"Alpha-aminoadipic and alpha-ketoadipic aciduria","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0001263","is_excluded":false,"label":"Global developmental delay","onset_id":null,"reference":"PMID:23141293","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"693f28b4824dd33aa4759906148b62a937c841d7aa24e2354dc86841fcc3eff6","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"743bc3cc6a3a2856e0086e2df23223c0822c245d3215c212e33c5c8878bfa567","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0007018","is_excluded":false,"label":"Attention deficit hyperactivity disorder","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"79d56fdafa064d9cbb4076337329a1145433ae7c9b46510a0e567456de185c25","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000717","is_excluded":false,"label":"Autism","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"8d15e9bffe27ff31552bee24f5957c89112aef3feeb6a955392b0c1dce00b3e3","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0034465","is_excluded":false,"label":"2-hydroxyadipic aciduria","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"9a4c90eb3c60570106c5e0d55053309fd2e83871c49572b862b0da8d57bab820","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:204750","disease_name":"Alpha-aminoadipic and alpha-ketoadipic aciduria","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0034465","is_excluded":false,"label":"2-hydroxyadipic aciduria","onset_id":null,"reference":"PMID:23141293","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"9f4062cd3b272387ed78b0b25fa62fe9c8ea0dcbdbc255613be9a021298daab3","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204750","disease_name":"Alpha-aminoadipic and alpha-ketoadipic aciduria","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0000750","is_excluded":false,"label":"Delayed speech and language development","onset_id":null,"reference":"PMID:23141293","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"a668e9a7f658a805ea3e0c56d4f60ab234d13c75b48ebac99cd8a90a342ada84","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204750","disease_name":"Alpha-aminoadipic and alpha-ketoadipic aciduria","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0000252","is_excluded":false,"label":"Microcephaly","onset_id":null,"reference":"PMID:23141293","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"ad3abd590acfcc4c8f5e0f4cb77928c16865b804cec161f2f702d096d7f8c22a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000252","is_excluded":false,"label":"Microcephaly","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"bfac1ae8319bdc3a754ffb8b381b5a045fd317294a18bc45cd2dccfe3072386d","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000750","is_excluded":false,"label":"Delayed speech and language development","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c8db93f3d52e31cc0dbff8799e6f018709b90e932d6b5ef82a864308344c61ef","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:6000278","is_excluded":false,"label":"Elevated circulating 2-aminoadipic acid concentration","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"ddc1fbfca1b12ce2e83388836d13584ead3a0abdb67e6930c309a0e8d4f8636f","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79154","disease_name":"2-aminoadipic 2-oxoadipic aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001263","is_excluded":false,"label":"Global developmental delay","onset_id":null,"reference":"ORPHA:79154","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"fce96f6caa465e6fcdd6025af0e517474dc553ce524b20e36983f3000fc20e08","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:204750","disease_name":"Alpha-aminoadipic and alpha-ketoadipic aciduria","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0001252","is_excluded":false,"label":"Hypotonia","onset_id":null,"reference":"PMID:23141293","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/16708\" rel=\"noreferrer\">GARD</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>ORPHA:79154</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>A rare disorder of lysine and tryptophan metabolism characterized by 2-aminoadipic and 2-oxoadipic aciduria. Patients may also present with increased urinary excretion of alpha-hydroxyadipic acid. Variable clinical presentations have been found in patients including hypotonia, developmental delay, mild to severe intellectual disability, ataxia, epilepsy, and behavioral disorders (most commonly attention deficit hyperactivity disorder). However, many individuals with the biochemical phenotype are completely asymptomatic and thus the clinical significance of the condition is questionable.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/16708\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"2-aminoadipic-2-oxoadipic-aciduria","sourceDocuments":[{"name":"GARD: 2-aminoadipic 2-oxoadipic aciduria","reviewed":null,"source_release":"2026-10-21T17:01:20Z","url":"https://rarediseases.info.nih.gov/diseases/16708"}],"sourceNote":"","synonyms":["2-aminoadipic 2-oxoadipic aciduria","alpha-aminoadipic aciduria","alpha-aminoadipic and alpha-ketoadipic aciduria","AMOXAD","Ketoadipicaciduria"],"takeawayHtml":"","title":"2-aminoadipic 2-oxoadipic aciduria"},"schemaVersion":1}
